UK "Stopping GW Drug Exports to Iraq"
The Iraqi Ministry of Health has claimed that the UK government prevented Glaxo Wellcome from sending Iraq "the medicines used to treat the sick who suffer from angina pectoris" as well as anesthesia materials used for Caesarean sections. Health Minister Midhat Mubarak said in Baghdad that the government was still preventing Glaxo Wellcome from exporting.
He also said the USA and UK had "forced some states to hide medical and scientific information from Iraqi physicians," and prevented them from taking part in world scientific conferences. Medicines needed to keep alive more than 600,000 Iraqis suffering from chronic diseases such as hypertension, diabetes and cancer cost some $200 million annually, he said.
A spokeswoman for GW told the Marketletter that she was unaware of these claims, and no further information was forthcoming as the journal went to press.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze